Nutriband Responds to Fentanyl Executive Order, Highlights Development of Abuse-Deterrent Patch

Nutriband Inc. (NASDAQ: NTRB) responded to the Trump Administration Executive Order designating illicit fentanyl and its core precursor chemicals as weapons of mass destruction, emphasizing that this designation should not be conflated with FDA-approved prescription fentanyl therapies. The company stated that transdermal fentanyl patches are produced under rigorous regulatory oversight and remain medically necessary for certain severe chronic pain patients. This distinction comes amid ongoing concerns about transdermal fentanyl patch abuse and accidental pediatric exposure, issues that have prompted regulatory and public health attention.

The company is partnering with Kindeva to develop AVERSA™ FENTANYL, which combines Nutriband's AVERSA™ abuse-deterrent technology with Kindeva's FDA-approved fentanyl patch. This collaboration aims to create a product that deters abuse and reduces accidental exposure while maintaining access for patients who need prescription fentanyl products. According to Nutriband, AVERSA™ FENTANYL could be the first abuse-deterrent opioid patch on the market, addressing a significant gap in pain management options. The technology is designed to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential, as detailed on the company's website at https://www.nutriband.com.

Nutriband projects that AVERSA™ FENTANYL has the potential to reach peak annual U.S. sales of $80 million to $200 million, with an initial focus on the U.S. market and a stated goal of broader availability in major global medical markets. This development represents a strategic response to both regulatory actions and public health needs, positioning the company at the intersection of pharmaceutical innovation and opioid safety. The full press release is available at https://ibn.fm/AHvva, providing additional context on the company's initiatives.

The importance of this announcement lies in its dual focus: clarifying the distinction between illicit and medical fentanyl while advancing a solution to mitigate risks associated with prescription patches. As opioid-related concerns continue to shape healthcare policy and practice, products like AVERSA™ FENTANYL could offer a balanced approach to pain management and safety. For ongoing updates, investors can refer to the company's newsroom at https://ibn.fm/NTRB, which covers developments related to Nutriband and its portfolio.